Anixa Biosciences is trading 6.1% up at $3.67 today, driven by a broader biotech sector rally and positive sentiment surrounding its oncology pipeline.
- The move follows recent progress updates on the company's ovarian cancer CAR-T program and breast cancer vaccine.
- No fresh, stock-specific news or major corporate events were reported today, suggesting the gain is primarily fueled by sector momentum and risk-on market conditions.